People with type 2 diabetes often also have hypertension (high blood pressure), which increases their risk of developing chronic kidney disease and kidney failure. However, controlling blood pressure is effective in slowing the progression of kidney disease, as well as reducing the risk of cardiovascular events.
Dihydropyridine calcium-channel-blockers (DCCBs) are widely used as an extra therapy to treat hypertension in people with type 2 diabetes, alongside renin–angiotensin system inhibitors (RASi) and sodium–glucose cotransporter-2 inhibitors (SGLT2i). Now, a study presented at the 63rd European Renal Association Congress in Glasgow, United Kingdom, suggests that DCCBs could be associated with poorer kidney outcomes in people with type 2 diabetes.
The research found that DCCB use was associated with a 33% higher risk of major adverse kidney events, when compared with other hypertension treatments used with people with type 2 diabetes. The Association of British Clinical Diabetologists (ABCD) told Medical News Today : “Treatment of hypertension is crucial in the management of diabetic kidney disease (DKD).
Medical News Today published a clinical update in Research Highlights on 07 Jun 2026.
The item focuses on Could a common blood pressure drug worsen kidney disease in type 2 diabetes?.
Review the original article for the full source wording and details.